PET/MRI and plaque vulnerabilityA feasibility study of 18F-Flutemetamol in atherosclerosis - PET/MRI and plaque vulnerability: Flutemetamol

Maastricht University Medical Center0 个研究点目标入组 25 人开始时间: 2016年11月3日最近更新: 2020年11月3日

适应症

试验速览

暂无简介。

•Age 18 years and older (no maximum age)
•Informed consent by signed informed consent form regarding this study
•Either: Patients, who are scheduled for carotid endarterectomy (CEA)
•Or: Patients who are not scheduled to undergo a CEA, but have experienced a TIA/CVA/amaurosis fugax within the last 14 days and at least a 30% stenosis of the symptomatic carotid artery as based on flow velocities with duplex ultrasonography.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 5
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Severe cognitive impairment, neurological deficit or comorbidity causing the study to be too high a burden for the patient or disrupting patient’s co-operation with scan procedures.
•Evident other causality for stroke (cardiac embolus, small vessel disease, carotid dissection or thrombogenic diathesis).
•Pregnant women and nursing mothers.
•Contra-indications for MRI.
•?Relative contra-indications for MRI-contrast agent: GFR <30ml/min/1,73m2/Previous allergic reaction to MRI contrast agent.
•Contra-indication Flutemetamol: Hypersensitivity to the active substance or to any of the excipients

发起方